AlphaGrep UK
NBIX icon

AlphaGrep UK’s Neurocrine Biosciences NBIX Stock Holding History

AlphaGrep UK’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$354K Buy
+2,496
New +$401K 0.11% 408
2026
Q2 		– Sell
-4,252
Closed -$560K – 882
2026
Q1 		$560K Buy
4,252
+91
+2% +$12.1K 0.16% 194
2025
Q4 		$590K Buy
+4,161
New +$603K 0.2% 157

Other funds holding NBIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

AlphaGrep UK's NBIX Position: Q3 2026 in Review

AlphaGrep UK opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 2,496 shares worth $354K. The stake represents 0.11% of the portfolio and ranks #408 among its holdings. This is a return to the name: AlphaGrep UK previously reported a position in NBIX as recently as Q1 2026.

AlphaGrep UK first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $590K in Q4 2025. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • AlphaGrep UK held 2,496 shares of Neurocrine Biosciences worth $354K as of Q3 2026.
  • Neurocrine Biosciences was a new AlphaGrep UK position in Q3 2026.
  • Neurocrine Biosciences made up 0.11% of AlphaGrep UK's portfolio in Q3 2026, its #408 holding.
  • AlphaGrep UK first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • AlphaGrep UK's Neurocrine Biosciences position peaked at $590K in Q4 2025.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.